Physician profile
Michael J Robichaud
NPI 1801998000
$1,717.96
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,589 · 2022: $129.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $370.29 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $208.14 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $196.91 | 2021 | |
| Arbor Pharmaceuticals, INC. | $131.52 | 2021 | |
| Amgen INC. | $116.99 | 2021 | |
| Ibsa Pharma INC. | $102.05 | 2021 | |
| Virtus Pharmaceuticals LLC | $91.46 | 2021 | |
| Biodelivery Sciences International, INC. | $72.14 | 2021 | |
| Redhill Biopharma INC. | $61.55 | 2021 | |
| Abbvie INC. | $51.01 | 2021-2022 | |
| Eisai INC. | $49.17 | 2021-2022 | |
| Nalu Medical, INC. | $46.78 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $42.85 | 2021 | |
| Forte Bio-Pharma LLC | $41.69 | 2021 | |
| Pfizer INC. | $39.68 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $21.40 | 2021 | |
| Grt US Holding, INC. | $21.30 | 2021 | |
| Collegium Pharmaceutical, INC. | $14.89 | 2021 | |
| Currax Pharmaceuticals LLC | $14.51 | 2021 | |
| Scilex Pharmaceuticals INC. | $11.89 | 2021 | |
| Almatica Pharma LLC | $11.74 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Robichaud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.